Fmoc-trans-4-Hydroxy-D-proline
Product Code：B201361
English Name：Fmoc-trans-4-Hydroxy-D-proline
English Alias：(2R,4S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-hydroxypyrrolidine-2-carboxylic acid
CAS No.：139262-20-7
Molecular Formula：C₂₀H₁₉NO₅
Molecular Weight：353.37
High Purity：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for precise modification of trans-hydroxyproline derivatives in peptide synthesis.
Excellent Stability：Stable for 36 months at -20℃ under light-protected, sealed storage; well-soluble in common organic solvents (e.g., DMF, DCM) with degradation rate <0.5% within 6 months, ensuring synthesis reliability.
Peptide Drug Synthesis：As an Fmoc-protected trans-D-hydroxyproline monomer, used in solid-phase peptide synthesis (SPPS) to construct functional peptides containing hydroxyproline, such as antimicrobial peptides and enzyme inhibitors.
Drug Development Tool：Modulates peptide conformational stability and biological activity by introducing trans-hydroxyproline structure in new drug development, e.g., enhancing peptide transmembrane ability or target affinity.
Biochemical Research：Used to study protein-ligand interactions or as a probe molecule to regulate peptide secondary structures (e.g., β-sheets), optimizing molecular recognition via hydroxyl hydrophilicity.
Hydroxyproline is a key component of natural proteins like collagen, with its configuration crucial for maintaining protein spatial structure. Fmoc-trans-4-Hydroxy-D-proline, as an Fmoc-protected trans-D-isomer, protects the amino group with fluorenylmethoxycarbonyl (Fmoc) to avoid racemization during synthesis while retaining 4-hydroxy reactivity. This compound introduces rigid structural units in peptide drug design, often used to develop therapeutic peptides with specific conformations, such as antiviral and antitumor drugs.
Synthesis Process：Prepared by condensation of Fmoc-Cl with trans-D-hydroxyproline under alkaline conditions (e.g., NaHCO₃/DCM system), with optimized reaction temperature (0-5℃) and purification (reverse-phase preparative HPLC), yielding over 70%.
Application Progress：Recent studies show that peptides containing this monomer exhibit excellent activity in treating fibrotic diseases, such as reducing collagen deposition by inhibiting TGF-β signaling; additionally, used as a linker component in ADC drugs to modify antibodies or toxin molecules via hydroxyl groups, improving conjugate stability.
Analytical Techniques：Circular dichroism (CD) and X-ray crystallography verify β-turn structures induced in peptides, while UPLC-MS/MS monitors impurities (e.g., cis-isomers, deprotected products) during synthesis to ensure product uniformity.
WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
